Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 85

Results For "2022"

1412 News Found

BioIVT promotes Dr. Richard Haigh to CEO
People | August 02, 2022

BioIVT promotes Dr. Richard Haigh to CEO


Cipla posts Q1FY23 consolidated PAT at Rs. 686.40 Cr
News | July 31, 2022

Cipla posts Q1FY23 consolidated PAT at Rs. 686.40 Cr

he company has reported total income of Rs. 5478.62 crores during the period ended June 30, 2022.


Torrent Pharmaceuticals posts Q1FY23 consolidated PAT Rs. 354 Cr
News | July 31, 2022

Torrent Pharmaceuticals posts Q1FY23 consolidated PAT Rs. 354 Cr

Torrent Pharmaceuticals has reported total income of Rs. 2377 crores during the period ended June 30, 2022.


Casper Pharma completed USFDA pre-approval inspection
Drug Approval | July 31, 2022

Casper Pharma completed USFDA pre-approval inspection

The audit is part of the agency's inspection for three product applications filed and slated to be manufactured at this site.


GMM Pfaudler Q1FY23 consolidated PAT surges to Rs. 44.51 Cr
News | July 29, 2022

GMM Pfaudler Q1FY23 consolidated PAT surges to Rs. 44.51 Cr

GMM Pfaudler has reported total income of Rs. 767.73 crores during the period ended June 30, 2022


Biocon Q1FY23 consolidated PAT falls QoQ at Rs. 144.4 Cr
News | July 28, 2022

Biocon Q1FY23 consolidated PAT falls QoQ at Rs. 144.4 Cr

Biocon has reported total income of Rs. 2217.4 crores during the period ended June 30, 2022.


Novartis India Q1FY23 PAT jumps to Rs. 52.38 Cr
News | July 28, 2022

Novartis India Q1FY23 PAT jumps to Rs. 52.38 Cr

Novartis India has reported total income of Rs. 147.44 crores during the period ended June 30, 2022.


Dr. Reddy's launches Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market
Drug Approval | July 28, 2022

Dr. Reddy's launches Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market

The Velcade Brand and generic had U.S. sales of approximately $1.2 billion MAT for the most recent twelve months ending in May 2022


Dr Lal Path Labs Q1 FY23 consolidated PAT drops to Rs. 57.7 Cr
News | July 28, 2022

Dr Lal Path Labs Q1 FY23 consolidated PAT drops to Rs. 57.7 Cr

Dr. Lal Path Labs has reported total income of Rs. 511 crores during the period ended June 30, 2022